BACKGROUND: Immune responses to mismatched donor human leukocyte antigens (HLA) are important in the pathogenesis of chronic rejection. This study evaluated whether erythrocyte-bound C4d (E-C4d) is associated with known alloimmune and autoimmune markers of antibody-mediated rejection after human lung transplantation (LTx). METHODS: Flow cytometry was used to analyze 22 LTx recipients and 15 healthy individuals for E-C4d. Development of antibodies to donor-mismatched HLA (donor-specific antibody [DSA]) and antibodies to HLA were determined using the solid-phase method by Luminex. Development of antibodies to self-antigens, K-alpha-1-tubulin (KA1T) and collagen V (Col-V), were measured by enzyme-linked immunosorbent assay. C3d deposition in lung biopsy specimens was determined by immunohistochemical staining. RESULTS: Percent E-C4d (%E-C4d) levels were 19.9% in LTx patients vs 3.7% in healthy individuals (p = 0.02). DSA+ patients had higher E-C4d levels than DSA- patients (34.1% vs 16.7%, p = 0.02). In 5 patients with preformed anti-HLA, E-C4d levels were not significantly different vs 13 patients without detectable anti-HLA (p = 0.1). E-C4d levels were higher in patients who developed antibodies to KA1T (p = 0.02) and Col-V (p = 0.03). Recipients with C3d-positive tissue deposition had higher E-C4d levels than patients with C3d-negative biopsy results (p = 0.01). CONCLUSIONS: Increased %E-C4d levels are found in patients with positive DSA, high antibody titers to KA1T and Col-V, and have C3d+ lung biopsy findings. Therefore, %E-C4d can serve as a potential marker for antibody-mediated rejection after LTx.
BACKGROUND: Immune responses to mismatched donorhuman leukocyte antigens (HLA) are important in the pathogenesis of chronic rejection. This study evaluated whether erythrocyte-bound C4d (E-C4d) is associated with known alloimmune and autoimmune markers of antibody-mediated rejection after human lung transplantation (LTx). METHODS: Flow cytometry was used to analyze 22 LTx recipients and 15 healthy individuals for E-C4d. Development of antibodies to donor-mismatched HLA (donor-specific antibody [DSA]) and antibodies to HLA were determined using the solid-phase method by Luminex. Development of antibodies to self-antigens, K-alpha-1-tubulin (KA1T) and collagen V (Col-V), were measured by enzyme-linked immunosorbent assay. C3d deposition in lung biopsy specimens was determined by immunohistochemical staining. RESULTS: Percent E-C4d (%E-C4d) levels were 19.9% in LTxpatients vs 3.7% in healthy individuals (p = 0.02). DSA+patients had higher E-C4d levels than DSA- patients (34.1% vs 16.7%, p = 0.02). In 5 patients with preformed anti-HLA, E-C4d levels were not significantly different vs 13 patients without detectable anti-HLA (p = 0.1). E-C4d levels were higher in patients who developed antibodies to KA1T (p = 0.02) and Col-V (p = 0.03). Recipients with C3d-positive tissue deposition had higher E-C4d levels than patients with C3d-negative biopsy results (p = 0.01). CONCLUSIONS: Increased %E-C4d levels are found in patients with positive DSA, high antibody titers to KA1T and Col-V, and have C3d+ lung biopsy findings. Therefore, %E-C4d can serve as a potential marker for antibody-mediated rejection after LTx.
Authors: A B Collins; E E Schneeberger; M A Pascual; S L Saidman; W W Williams; N Tolkoff-Rubin; A B Cosimi; R B Colvin Journal: J Am Soc Nephrol Date: 1999-10 Impact factor: 10.121
Authors: L L Schulman; E K Ho; E F Reed; C McGregor; C R Smith; E A Rose; N M Suciu-Foca Journal: Transplantation Date: 1996-01-27 Impact factor: 4.939
Authors: A Jaramillo; M A Smith; D Phelan; S Sundaresan; E P Trulock; J P Lynch; J D Cooper; G A Patterson; T Mohanakumar Journal: Transplantation Date: 1999-04-27 Impact factor: 4.939
Authors: Susan Manzi; Jeannine S Navratil; Margie J Ruffing; Chau-Ching Liu; Natalya Danchenko; Sarah E Nilson; Shanthi Krishnaswami; Dale E S King; Amy H Kao; Joseph M Ahearn Journal: Arthritis Rheum Date: 2004-11
Authors: Stuart C Sweet; Hyunsook Chin; Carol Conrad; Don Hayes; Peter S Heeger; Albert Faro; Samuel Goldfarb; Ernestina Melicoff-Portillo; Thalachallour Mohanakumar; Jonah Odim; Marc Schecter; Gregory A Storch; Gary Visner; Nikki M Williams; Karen Kesler; Lara Danziger-Isakov Journal: Am J Transplant Date: 2019-07-25 Impact factor: 8.086
Authors: Thomas J Lynch; Bethany A Ahlers; Anthony M Swatek; Vitaly Ievlev; Albert C Pai; Leonard Brooks; Yinghua Tang; Idil A Evans; David K Meyerholz; John F Engelhardt; Kalpaj R Parekh Journal: Transplantation Date: 2022-04-15 Impact factor: 5.385